Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $2.85M fell 3.8% year over year, behind the +7.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +52.0% a year.

Context

  • Stock-based compensation amounted to 35.8% of revenue in FY2025, down 366.6 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.8% toward the trailing-twelve-month pace of +7.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.85M+3.7% QoQ
Last fiscal yearDec 2025
$11.98M+12.8% YoY
LTMMar 2026
$11.86M+7.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.8%——
1 year+12.8%——
3-year CAGR+52.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.98M USD
Year-over-year change
+12.8%
4-year CAGR
+151.0%

Stock-Based Compensation vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.9% is the 4th highest of 11, against a peer median of -32.8%.
  • Stock-based compensation amounts to 36.3% of revenue for OBIO, versus a peer median of 79.9%.
OBIO Competitors
Stock-Based Compensation for OBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$15.77M USD-32.9%-11.7%22.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
IVVDInvivyd, Inc.LTM Mar 2026$11.51M USD-33.2%-18.7%20.6%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M USD-28.1%+4.4%5116.0%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$11.16M USD-32.8%+2.7%99.6%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M USD-60.8%-22.0%60.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026$8.17M USD-33.3%-9.2%59.0%
TARAProtara Therapeutics, Inc.LTM Mar 2026$4.36M USD+16.7%-17.0%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-63.8%——
Peer median (excluding OBIO) —-32.8%-9.2%79.9%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Depreciation & Amortization181K222K287K308K327K
Deferred Income Tax288K0000
Stock-Based Compensation302K3.41M7.63M10.62M11.98M
Change in Working Capital2.6M(451K)(3.31M)(765K)(10.37M)
Accounts Receivables47K25K(3K)22K(3K)
Inventory1K(208K)131K(28K)(137K)
Accounts Payables1.08M0145K2.97M0
Other Working Capital1.47M(268K)(3.58M)(3.73M)(10.23M)
Other Non-Cash Items217K1.14M(1.61M)308K1.81M
Operating Cash Flow(19.43M)(29.29M)(46.13M)(50.56M)(48.96M)
Capital Expenditures(274K)(591K)(78K)(289K)(489K)
Acquisitions (Net)(13.29M)00(602K)0
Purchases of Investments(213K)(63.53M)(142.03M)(72.65M)(76.31M)
Sales of Investments13.5M0152.8M86.63M49.86M
Other Investing Activities13.29M0000
Investing Cash Flow13.02M(64.12M)10.69M13.09M(26.94M)
Debt Repayment(4M)3.55M(10.85M)15M17.91M
Common Stock Issued7K109.83M254K15.04M71.97M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7K(10.13M)56.81M(864K)(1.55M)
Financing Cash Flow(3.99M)103.26M46.22M29.17M88.33M
Effect of Forex Changes00000
Net Change in Cash(10.41M)9.85M10.78M(8.3M)12.43M
Free Cash Flow(19.7M)(29.88M)(46.21M)(50.85M)(49.45M)

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.